RB1 and small cell lung carcinoma: Additionally, loss of function mutations in RB1 and PTEN are prevalent in SCLC and lead to the dysregulation of multiple signaling pathways, including PI3K/AKT/mTOR, RAS/RAF/MEK/ERK, and NOTCH1 signaling, contributing to the aggressive nature of this disease.